PSPavel V. Svirin

Pavel V. Svirin

*This is an algorithmically generated author record based on publicly available information.

Pavel V. Svirin has a total of 107 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Approaches to the treatment of ischemic stroke in children

    by A. A. Kuznetsova, I. O. Shchederkina, L. E. Larina, P. V. Svirin, A. E. Kessel, M. I. Stepanenko, I. N. Lavrentieva, S. A. Tulupova, A. A. Tsaturova, A. M. Kozlova, et al.

    Background. There are no standardised protocols for the treatment of ischaemic stroke in children to date. Objective. To evaluate outcomes in patients with a confirmed diagnosis of acute arterial ischaemic stroke who received antithrombotic therapy at the Centre for Cerebrovascular Diseases in Children and Adolescents (the Centre) based at the Morozovskaya Children's City Clinical Hospital of the Moscow City Health Department. Materials and methods. A single-centre retrospective study was conducted, including 145 patients with confirmed arterial ischaemic stroke between 2019 and 2023. All patients underwent a comprehensive examination, including assessment of neurological status using the PedNIHSS scale, neuroimaging (MRI with angiography), extensive laboratory testing of the haemostasis system, and cardiac and vascular evaluation. Aetiological classification was performed according to the CASCADE criteria. Four antithrombotic therapy regimens were used: anticoagulant therapy with unfractionated heparin with or without transition to low molecular weight heparin, or monotherapy with low molecular weight heparin – 21 patients (14.5%); monotherapy with acetylsalicylic acid – 25 patients (17.2%); combination therapy with transition from heparins to acetylsalicylic acid within 3-6 months – 99 patients (68.3%). Doses were adjusted based on anti-Xa activity monitoring. Systemic thrombolysis with alteplase was performed in 17 patients (11.7%). Long-term outcomes were assessed at a median of 41 months using the modified Rankin Scale and the PSOM scale. Statistical analysis was performed using non-parametric methods. Results. In this cohort the median age was 4 years 5 months; 64.8% were boys. Aetiology remained undetermined in 21.4% of cases; arteriopathies were identified in 18.6%, and multifactorial genesis in 15.9%. Thrombolytic therapy was administered to 17 patients (11.7%). No statistically significant differences in long-term outcomes were found between the different antithrombotic therapy regimens. Recurrent stroke was recorded in 8.3% of patients. Post-stroke epilepsy developed in 9.3% and was associated with more severe neurological deficit (p < 0.05). In patients with cardioembolic stroke in the perioperative period, a significant decrease in antithrombin III activity (p = 0.005) and protein C activity (p = 0.006) was observed. In the group of patients with post-stroke epilepsy, long-term outcomes were significantly worse than in patients without epilepsy, which likely indicates a negative impact of epileptogenesis on neuroplasticity processes. Thrombolytic therapy was not associated with severe bleeding or recurrences. However, its benefits require further study due to the lack of randomisation. Conclusion. Anticoagulants, antiplatelet agents, and thrombolysis are used in the treatment of acute arterial ischaemic stroke in children, but to date, no proven advantages of any specific treatment regimen for arterial ischaemic stroke in children have been established.

  • Open Access

    Clinical case of successful thrombolysis in a newborn with thrombosis of the left renal vein

    by Anastasiya A. Fomushkina, Oksana V. Voronina, Elena V. Karpysheva, Yuliia Yu. Mitina, Andrei Yu. Yelkov, Pavel V. Svirin, Julia V. Zhirkova, Митина Юлия Юрьевна, Елков Андрей Юрьевич

    Thrombosis occurring in the neonatal period is a nosology with a large number of complications, often leading to disability and death. This article highlights the successful treatment of a newborn child with renal vein thrombosis using systemic thrombolysis. A clinical case of successful systemic thrombolysis in a full-term boy in the early neonatal period with thrombosis of the left renal vein and transition of the floating part of the thrombus to the inferior vena cava is presented. A child aged 3 days was admitted to the neonatal intensive care unit from a maternity hospital, where thrombosis was suspected. Gross hematuria was observed. Laboratory data revealed thrombocytopenia and increased levels of fibrinogen and D-dimer. Ultrasound showed a sharp increase in the volume of the left kidney, a diffuse change in its parenchyma, a sharp depletion of blood flow, and accumulation of fluid in the perinephric tissue on the left, and a thrombus was observed in the lumen of the left renal vein with the presence of a floating part extending into the inferior vena cava. Thrombolytic therapy with the drug alteplase was started in combination with an infusion of unfractionated heparin. Doses were selected based on coagulogram parameters. On day 2 of therapy, hematuria resolved. On day 4 of therapy, the alteplase infusion was completed, and heparin therapy was continued. On day 13, the child was switched to a low-molecular-weight-heparin therapy. Dynamic ultrasound revealed size reduction, recanalization and further thrombus lysis, and normalization of intrarenal blood flow and kidney size. No renal dysfunction was recorded during observation. The child was transferred to the further care unit at aged 14 days and was discharged home at the age of 25 days in satisfactory condition on ongoing anticoagulant therapy under outpatient supervision of a hematologist. During follow-up observation at aged 1.5 months of life, no clinical, laboratory, and ultrasound indicators of renal function disorders were noted. Currently, there are no approved recommendations and protocols for individual thrombosis in newborns, although this particular age group is due to the vulnerability of hemostasis to the development of a thrombotic process.

  • Open Access

    Statistically significant improvement in hemophilia A control: a retrospective analysis of the effectiveness and safety of emicizumab in children with severe and inhibitor forms of hemophilia A

    by V. Yu. Petrov, I. N. Lavrentyeva, V. V. Vdovin, P. V. Svirin

    Hemophilia A presents a serious problem, especially in its severe and inhibitor forms, leading to severe bleeding and complications. The importance of studying the effectiveness and safety of new treatment approaches, particularly emicizumab, is undeniable for improving the quality of life of patients.   Aim: to evaluate the effectiveness and safety of emicizumab in the prevention of bleeding in children with severe and inhibitor forms of hemophilia A. Ethical approval was not required since the study only involved the use of generalized retrospective data obtained during routine clinical practice. All data were depersonalized. A retrospective analysis of medical records of 45 children treated at the Morozov Children's Hospital from 2006 to 2022 was carried out. The study included two cohorts: those with severe hemophilia A and those with inhibitor forms. The analysis included an assessment of the frequency of bleeding and hemarthrosis episodes, hospital admissions, and adverse reactions. The analysis included data from 45 patients with hemophilia A who underwent treatment with emicizumab from 2018 to 2022. Of these, 30 children had a severe form of hemophilia A, and 15 had an inhibitor form. The median follow-up period for a severe form was 17 months, ranging from 12 to 23 months, while for an inhibitor form, it was 32 months, with a range of 11 to 51 months. In the group with severe hemophilia A, a statistically significant (p < 0.001) reduction in the frequency of all types of bleeding was observed: 96.7 % of children had no episodes of hemarthrosis during emicizumab therapy, compared to 46.7 % of patients previously treated with FVIII concentrates. No spontaneous hemarthrosis was registered. Similar results were observed in the group with an inhibitor form of hemophilia A: 93.3 % of children had no hemarthrosis episodes while using emicizumab compared to 13.3% during previous treatment with bypassing agents. Over the entire follow-up period, there were 3 bleedings in the cohort of children with severe hemophilia A and 1 bleeding in the cohort of children with inhibitor hemophilia A. Prior to the use of emicizumab, out of 391 bleeding episodes that occurred in 45 children, 218 were spontaneous. Adverse events were recorded in 7 children, manifesting as erythema at the injection site after the first or first and second emicizumab injections and resolving spontaneously. There were no other adverse events; 90 % of children with severe hemophilia A and 73.3 % of children with inhibitor hemophilia A did not report any adverse events during the use of emicizumab. Emicizumab demonstrates high effectiveness and safety in the treatment of children with severe hemophilia A, both with and without inhibitors. The drug significantly reduces the frequency of bleeding episodes and improves the quality of life of patients.

  • Resolution by the Expert Council on the use of the Valoctocogene Roxaparvovec drug in patients with Hemophilia A in Russia

    by A.G. Rumyantsev, Oncology And Immunology Named After Dmitry Rogachev National Scientific And Practical Center For Pediatric Hematology, T.A. Andreeva, P.A. Zharkov, N.I. Zozulya, A.N. Mamaev, P.V. Svirin, A.P. Momot, Saint Petersburg Saint Petersburg City Polyclinic No. 37

  • THROMBOLYTIC THERAPY IN PEDIATRIC PRACTICE: A BIBLIOGRAPHICAL REVIEW (PART 2)

    by Moscow Morozov Children’s City Clinical Hospital, P.V. Svirin, L.E. Larina, I.N. Lavrentyevа

    Part 2 of the Article represents published data dedicated to the thrombolytic therapy (TT) for thrombosis of various localizations in children. Options for dosing and methods of thrombolytic therapy are considered. Indications and contraindications for this method of treatment are described. information on thrombolytic therapy in newborns is provided as well. Part 1 of the Article is available at https://doi.org/10.24110/0031-403X-2023-102-3-145-150: P.V. Svirin, L.E. Larina, I.N. Lavrentyeva. Thrombolytic therapy in pediatric practice (Part 1). Pediatria n.a. G.N. Speransky. 2023; 102 (3): 145-150. DOI: 10.24110/0031-403X-2023-102-3-145-150.

  • THROMBOLYTIC THERAPY IN PEDIATRIC PRACTICE (PART 1)

    by Moscow Morozov Children’s City Clinical Hospital, P.V. Svirin, L.E. Larina, I.N. Lavrentyevа

    Thromboses in children represent the serious pathology that can lead to disability and even death of a pediatric patient. At certain localizations of thrombosis, the most rapid restoration of vascular patency (reperfusion) becomes prognostically significant. The most accessible method for reperfusion is drug therapy, in which a drug is injected into the patient's blood, which in its turn significantly accelerates the process of fibrinolysis, i.e., thrombolytic therapy (TT). The purpose of this bibliographical review was to familiarize physicians, especially pediatricians with the place of TT in modern clinical practice. The article represents bibliographical review of published works for over 50 years (since 1966). Authors have used both domestic Russian resources and the PUBMED database. Articles were selected based on the relevance. Statistical analysis was not performed. A review and analysis of bibliographical data on the modern use of TT in pediatric practice is presented. Preference was given to the most modern publications containing analytical information with full text available both pro bono and online. Authors emphasize pediatric practitioners’ attention on the fact that TT at the current level of knowledge is a fairly effective and predictable method for rapid reperfusion.

  • RESULTS OF OPEN, PROSPECTIVE, MULTICENTER, NON-COMPARATIVE STUDY OF NONACOG ALPHA PHARMACOKINETICS, EFFICACY AND SAFETY IN CHILDREN AGED 2–12 YEARS WITH SEVERE AND MODERATE HEMOPHILIA В

    by Saint Petersburg Saint Petersburg City Polyclinic No. 37, T.A. Andreeva, V.V. Lebedev, Krasnodar Krasnodar Krai Regional Children'S Clinical Hospital, V.V. Vdovin, Moscow Morozov Children’s City Clinical Hospital, M.A. Timofeeva, I.L. Davydkin, I.A. Lavrichenko, O.A. Krasheninnikova, et al.

    The aim of the study was to evaluate the efficacy, safety and pharmacokinetics of nonacog alfa (Innonafactor) in children aged 2 to 12 years with hemophilia B. Materials and methods: 15 patients (7.7±2.5 years ) were included in an open, multicenter, prospective, non-comparative clinical trial, of whom 12 were aged 6 to 12 years and 3 were aged 2 to 6 years. The efficacy of the drug was assessed against the background of the introduction of 45±10 IU/kg 2 times a week with an interval of 72–96 hours, the safety was assessed by the frequency and nature of adverse reactions. Results: 5 (22%) spontaneous and 18 (78%) post-traumatic bleedings were registered. The mean number of spontaneous bleeding within 72 hours after administration of nonacog alfa was 2±1.4. The average prophylactic dose was 47.74±6.47 IU/kg (Me 48.2 IU/kg). An average of 2.2±2.1 injections was required to stop a bleeding episode. 19 adverse events have been reported that are not related to nonacog alfa. Conclusion: the obtained data indicate the efficacy and safety of nonacog alfa in the study group of patients. Thus, the data obtained indicate the efficacy and safety of Innonafactor drug both for prophylactic treatment and for the relief of bleeding in patients aged 2 to 12 years with severe and moderate hemophilia B.


  • SPECIFICITY OF THE MOROCTOCOG ALPHA MOLECULE: RESULTS OF A PROSPECTIVE, MULTICENTER, OPEN-LABEL, OBSERVATIONAL STUDY OF EFFICACY AND SAFETY IN CHILDREN AGED 12 TO 18 YEARS WITH HEMOPHILIA A

    by Moscow Morozov Children’s City Clinical Hospital, V.V. Vdovin, M.V. Kosinova, E.V. Kalinina, Samara Samara City Children’s Clinical Hospital No. 1 Named After N.N. Ivanova, M.A. Timofeeva, G.N. Mustafina, Kirov Kirov Oblast Regional Children’s Clinical Hospital, A.V. Rogov, Stavropol Stavropol Krai Regional Children'S Clinical Hospital, et al.

    The main method of treatment for hemophilia A is replacement therapy with drugs of blood coagulation factors VIII (FVIII). The active use of biotechnological methods in the production of recombinant drugs contributes to the development and registration of new FVIII drugs. The results of clinical trials of drugs in children usually include a limited number of patients for a specific period of time. Post-marketing observational studies provide additional information on the results of using a new drug in patients in clinical practice. The objectives of the study were to collect and analyze data on the efficacy and safety of domestic recombinant FVIII with a deleted B-domain, moroctocog alfa (Octofactor, GENERIUM JSC) in the treatment of adolescents aged 12–18 years with hemophilia A in routine clinical practice. Materials and methods of research: a prospective multicenter open-label observational study of the results of using the Octofactor in adolescents with hemophilia A (№ OCF-HPA-N01) included 24 male patients with severe hemophilia A aged 12 to 18 years (mean age 14,8±1,7 years), who received moroctocog alfa in routine clinical practice. Enrollment in the study was carried out after the signing of the informed consent form by the parent of the minor patient and the minor patient aged 14 to 18 years, taking into account the results of the screening examination. The follow-up period was 52±4 weeks, which, presumably, was sufficient to achieve at least 100 days of moroctocog alfa administration. To assess the effectiveness, we analyzed the incidence of spontaneous bleeding that occurred within 48–72 h after drug administration; the severity of spontaneous bleeding against the background of prophylactic treatment with moroctocog alfa, the number of injections and the dose of the study drug for prophylactic treatment, as well as for treatment at the request of one episode of bleeding, taking into account its severity; the researcher's determination of the response to treatment of acute hemarthrosis according to the scale of the World Federation of Hemophilia (2020). To assess safety, the frequency and characteristics of adverse events (AEs) associated with drug administration were analyzed, including the frequency of formation of an inhibitor to FVIII. Results: during the study, 59 bleedings were recorded, of which 21 (36%) were spontaneous and 38 (64%) were post-traumatic. Among spontaneous bleeding episodes, 5 (24%) episodes occurred within 48–72 hours after administration of the study drug. Spontaneous bleeding within 48–72 hours after administration of Octofactor was absent against the background of prophylactic treatment in most patients (81%) and was observed rarely during the observation period (1–3 times) in the remaining 19% of patients. The median number of bleeding within 48–72 h after study drug administration was 1 episode over the follow-up period. The proportion of mild to moderate bleeding was 97 [88; 100]% among all types of bleeding and 100 [84; 100]% among spontaneous bleeding within 48–72 hours after administration of the Octofactor drug. The median of a single dose of Octofactor for preventive treatment was 2000 [1500; 2000] IU or 31,7 [25,6; 38,5] IU/kg, and with treatment on demand ‒ 2000 [2000; 3000] IU or 34,1 [28,8; 38,5] IU/kg per single injection. To stop the resulting bleeding required 1 [1; 2] introduction in a single dose of 3000 [2000; 4000] IU; the average dose was 4490 ÷ 4993 IU. When doctors subjectively assess the response to treatment of acute hemarthrosis on the scale of the World Federation of Hemophilia, an excellent response was noted in 9 (27%) episodes, good and moderate ‒ in 2 (6%) and 22 (67%) episodes, respectively. Lack of response to treatment of acute hemarthrosis with moroctocog alfa was not revealed in the study. During the study, 23 AEs were recorded in 13 (54%) patients not related to the study drug. Conclusion: thus, the obtained results of the study indicates the efficacy and safety of the Octofactor both the prophylactic treatment and treatment of on-demand bleedings in 12 to 18 year old patients with severe hemophilia A.


  • RESULTS OF THE OPEN MULTICENTER PROSPECTIVE CLINICAL STUDY OF THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF MOROCTOCOG ALPHA IN 6 TO 12 YEAR OLD CHILDREN WITH HEMOPHILIA A

    by M.A. Timofeeva, T.A. Andreeva, Saint Petersburg Saint Petersburg City Polyclinic No. 37, V.V. Vdovin, Moscow Morozov Children’s City Clinical Hospital, A.N. Mamaev, Barnaul Altai Krai Regional Clinical Hospital, I.L. Davydkin, V.V. Lebedev, Krasnodar Krasnodar Krai Regional Children'S Clinical Hospital, et al.

    Currently, the main method of treatment for hemophilia A is replacement therapy with drugs of blood coagulation factors VIII (FVIII). As a result of the development of new production technologies, recombinant FVIII are increasingly used for the treatment of hemophilia A. The justification for the use of new drugs in pediatric clinical practice requires careful preparation and clinical research studies of their efficacy and safety. The aim of this study was to evaluate the efficacy, safety and pharmacokinetics (PK) of domestic B-domain deleted recombinant factor VIII of Moroctocog alpha (Octofactor, GENERIUM JSC) in a cohort of children with hemophilia A aged 6 to 12 years in the framework of phase III clinical study of moroktocoga alpha in children 2 to 12 years old with hemophilia A. Materials and methods of the research: the age cohort of 6 to 12 years olds of an open multicenter prospective noncomparative study included 27 male children with severe hemophilia A (mean age 8,3±1,9 years). The study was carried out sequentially in 2 stages. Stage I included the study of PK parameters in 22 patients after a single study drug dose of 50 IU/kg. At stage II, the efficacy and safety of the drug was assessed in patients of stage I, as well as in additionally included 5 patients who received the study drug dose of 30±10 IU/kg per day every 2–3 days for 22±1 weeks of treatment. To assess the efficacy, we analyzed the incidence of spontaneous bleeding that occurred within 48–72 h after drug administration; the number of injections and the dose of FVIII used for prophylaxis, as well as for treatment on demand of one episode of bleeding, taking into account its severity; number of patients with severe hemophilia A with residual FVIII activity >/=1% 48–72 h after drug administration; the investigator's overall assessment of response to therapy on the acute hemarthrosis response scale. The main indicators for the analysis of PK properties were the area under the «concentration-time» curve, the half-life, the elimination constant, the increase in activity, and the degree of recovery of activity. To assess safety, the frequency of formation of an inhibitor to FVIII, the dynamics of vital and laboratory parameters, the frequency and characteristics of adverse events (AEs) associated with the administration of the drug were taken into account. Results: the area under the FVIII-time activity curve in the region of 0–48 h (AUC0-48) and with exponential extrapolation to infinity (AUC0-inf) was 731,82±264,94%*h and 756,11±270,16%*h, respectively. The half-life (T1/2) was 10,32±2,27 hours. In the examined age group, 78 bleeding were recorded, of which only 27 (35%) were spontaneous, including 24 (30%) episodes that occurred during 48–72 hours after the administration of drug under investigation. Haemorrhage within 48–72 hours after administration of the Octofactor drug was absent or was observed rarely (1–3 times) against the background of prophylactic treatment in most patients (88%), the median number of bleeding within 48–72 hours after administration of the study drug was 2 episodes per observation period. The proportion of spontaneous bleeding was the smallest in patients receiving a single prophylactic doses of the study drug 2000–3000 IU (7% of all bleeding), the largest proportion of spontaneous bleeding was observed in patients receiving a single prophylactic doses of the study drug 1000–2000 IU (70% of bleeding). The average single dose of Octofactor for preventive treatment was 1290,4±458,6 IU or 39,12±7,79 IU/kg, for on-demand treatment – 1641,7±722,4 IU per single injection. Of the 78 reported bleeding episodes, 68 (87%) required the study drug administration for relief, while the remaining 10 bleedings were selfcontained. On average, to stop bleeding, it took 1,5±0,8 injections of the drug on demand, median doses were 1 [1; 2], and average doses were 2434,3±1501,7 IU. During the study, 37 AEs were recorded in 15 (56%) patients. At the same time, 36 AEs (97%) were not associated with the drug under investigation, and one AE (allergic reaction), according to the researchers, was associated with the use of the drug. Thus, the analysis of data indicates the efficacy and safety of the Octofactor drug both the prophylactic treatment and treatment of on-demand bleeding in 6 to 12 year old patients with severe hemophilia A.


  • RESULTS OF AN OPEN, PROSPECTIVE, MULTICENTER, NONCOMPARATIVE STUDY OF THE PHARMACOKINETICS, EFFICACY AND SAFETY OF NONACOG ALFA IN PATIENTS AGED 6–12 YEARS WITH SEVERE AND MODERATE HEMOPHILIA B

    by Saint Petersburg Saint Petersburg City Polyclinic No. 37, T.A. Andreeva, V.V. Lebedev, Krasnodar Krasnodar Krai Regional Children'S Clinical Hospital, V.V. Vdovin, Moscow Morozov Children’s City Clinical Hospital, M.A. Timofeeva, I.L. Davydkin, I.A. Lavrichenko, O.A. Krasheninnikova, et al.

    Providing hemophilia patients with blood coagulation preparations is one of the priority tasks of the national health care system. In 2011, the first recombinant factor IX was created in Russia (rFIX, nonacog alpha, Innonafactor, GENERIUM JSC), that was previously studied for pharmacokinetic (PK) parameters, efficacy and safety in adult patients and adolescents over 12 years of age with severe and moderate hemophilia B. Objective of this open-label, prospective, multicenter, noncomparative clinical study was to study PK, efficacy and safety of Innonafactor in 12 patients aged 6 to 12 years with severe and moderate forms of hemophilia B (FIX activity less than 2%). The study included periods of screening, studies of PK parameters and treatment within 26±1 weeks, but not less than 50 days of administration of the studied drug. Nonacog alfa was administered in the study of PK parameters at a dose of 75 IU/kg, once, for prophylactic treatment – at a dose of 45±10 IU/kg, 2 times a week with an interval of 72–96 h. 30 minutes after administration of the studied drug, FIX activity increased to 73,93±13,35%, with a gradual decrease to 5,88±1,97% 72 hours after administration. The area under the «concentration ‒ time» curve in the section 0–72 h (AUC0–72) and with exponential extrapolation to infinity (AUC00‒∞) was 1573,41±407,16%*h and 1808,74 ± 437,59%*h respectively. Biological half-life (T1/2) was 28,11±8,60 hours. During preventive treatment there were 19 hemorrhagic episodes, 14 (74%) bleedings were post-traumatic and 5 (26%) bleedings were spontaneous. Mean number of bleeding episodes over the entire observation period was 1,9±1,4. Mean number of episodes of spontaneous bleeding that occurred within 72 hours after Innonafactor administration in patients with bleeding was 2,5±2,1. During the entire study period, patients received 942,5 thousand IU of the drug Innonafactor, 890,5 thousand IU were administered for prophylaxis and 52 thousand IU to stop bleeding on demand. Mean single dose of Innonafactor for prophylactic treatment was 46,24±5,86 IU/kg, for on-demand treatment – 49±13,1 IU/kg. Of the 19 registered bleeding episodes, 14 (73.7%) episodes required the administration of the studied drug; 5 (26,3%) bleedings stopped on their own. To stop one episode of bleeding, an average of 2,3±2,3 administration of nonacog alfa was required. At the end of the study, the proportion of hemophilia B patients with residual FIX activity of 2% or more was 92%. During the study, 14 adverse events (AEs) were registered in 7 (58,3%) patients. All reported AEs were not study drug related and did not require study drug withdrawal. Thromboembolic complications and immunogenic reactions were not registered. Thus, the data obtained indicate efficacy and safety of Innafactor both for prophylactic treatment and for on-demand treatment of bleeding in patients aged 6 to 12 years with severe and moderate hemophilia B.